These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37993281)

  • 1. Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.
    Xie H; Wen X; Wang Y; Huang X; Shu Q; Wang D; Geng L; Jin Z; Shen W; Ge W; Zhu Y; Sun L
    Lupus Sci Med; 2023 Nov; 10(2):. PubMed ID: 37993281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.
    Lee JY; Vinayagamoorthy N; Han K; Kwok SK; Ju JH; Park KS; Jung SH; Park SW; Chung YJ; Park SH
    Arthritis Rheumatol; 2016 Jan; 68(1):184-90. PubMed ID: 26316040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.
    Gao B; Tan T; Cao X; Pan M; Yang C; Wang J; Shuai Z; Xia Q
    BMC Med Genomics; 2022 Feb; 15(1):23. PubMed ID: 35135554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
    Yeon Lee J; Lee J; Ki Kwok S; Hyeon Ju J; Su Park K; Park SH
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):536-542. PubMed ID: 27390146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus.
    Pan M; Jin R; Dai Y; Gao B; Liu Y; Peng X; Qiao J; Shuai Z
    Int Immunopharmacol; 2024 Jan; 126():111269. PubMed ID: 38006753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.
    Sailler L; Puissant B; Méliani P; Castex JO; Saivin S; Adoue D; Fournie B; Arlet P; Montastruc JL; Lapeyre-Mestre M; Pourrat J; Blancher A
    Ann N Y Acad Sci; 2007 Jun; 1108():41-50. PubMed ID: 17893969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic susceptibility and clinical features of
    Luo X; Du J; Zhao J; Fan M; Luo X; Zhao P; Zheng P; Mo L; Li Y
    Lupus; 2024 Oct; 33(12):1328-1335. PubMed ID: 39287122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.
    Shimizu M; Furudate S; Nagai Y; Shimada K; Ohshima M; Setoguchi K; Hashiguchi M; Yokogawa N
    Mod Rheumatol; 2023 Aug; 33(5):953-960. PubMed ID: 36112484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.
    Huang X; Shu Q; Luo X; Ge W; Xie H; Zhou Y
    Rheumatol Ther; 2023 Dec; 10(6):1597-1607. PubMed ID: 37755649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
    Jallouli M; Galicier L; Zahr N; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Le Thi Huong D; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Leroux G; Cohen-Bittan J; Sellam J; Mariette X; Blanchet B; Hulot JS; Amoura Z; Piette JC; Costedoat-Chalumeau N;
    Arthritis Rheumatol; 2015 May; 67(8):2176-84. PubMed ID: 25989906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ; Day RO; Tett SE
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.
    Balevic SJ; Randell R; Weiner D; Beard C; Schanberg LE; Hornik CP; Cohen-Wolkowiez M; Gonzalez D;
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36328395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus.
    Noé G; Amoura Z; Combarel D; Lori L; Tissot N; Seycha A; Funck-Brentano C; Zahr N
    Ther Drug Monit; 2019 Aug; 41(4):476-482. PubMed ID: 30807538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence.
    Blanchet B; Jallouli M; Allard M; Ghillani-Dalbin P; Galicier L; Aumaître O; Chasset F; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Le Thi Huong D; Asli B; Kahn JE; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Leroux G; Cohen-Bittan J; Sellam J; Mariette X; Goulvestre C; Hulot JS; Amoura Z; Vidal M; Piette JC; ; Jourde-Chiche N; Costedoat-Chalumeau N
    Arthritis Res Ther; 2020 Sep; 22(1):223. PubMed ID: 32977856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
    Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
    Munster T; Gibbs JP; Shen D; Baethge BA; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; Lindsley H; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D; Furst DE
    Arthritis Rheum; 2002 Jun; 46(6):1460-9. PubMed ID: 12115175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.